Lumos Pharma to Participate in the Cantor Rare Disease Symposium. All of the above webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, About Marinus Pharmaceuticals. Vanda Pharmaceuticals Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. 60th European Society for Paediatric Endocrinology (ESPE) Meeting. Inversago Pharma to present at upcoming Oppenheimer Rare & Orphan Disease Summit to be held on Friday, May 21, 2021 – Inversago Pharma. Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. MONTREAL (CANADA) – May 20, 2021 – Inversago Pharma Inc., the peripheral CB1 blockade company, today announced that François Ravenelle, PhD, CEO and Founder, will be presenting at the Oppenheimer Rare & Orphan Disease Summit.
Lumos Pharma to Participate in Upcoming Investor Conferences. March 15 – 20, 2022AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission. Norfolk, VA, November 19, 2020 — Norfolk, Virginia, known globally for its expertise in resilience and strong entrepreneurship ecosystem, More. All forward-looking statements contained in this press release speak only as of the date on which they were made. Date: Time: Format: Fireside chat. For conferences that offer replays, presentations will be made available for a limited time. Gain Therapeutics - Events All. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Savara Third Quarter 2017 Financial Results & Business Update Call. About Casma Therapeutics.
For more information visit View source version on. Establish presence in Other serious chronic diseases focusing on. Marinus Pharmaceuticals, Inc. 484-253-6792. Jefferies 2017 London Healthcare Conference. Please note that any opinions, estimates or forecasts regarding Vanda Pharmaceuticals Inc. 's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vanda Pharmaceuticals Inc. or its management. Oppenheimer rare and orphan disease summit co. Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022. D. LifeSci Advisors, LLC. For more information, please visit Contacts.
Events & Presentations. D., president and chief executive officer, will participate in multiple conferences in May. About ReAlta Life Sciences. H. Wainwright Global Life Sciences Conference. Nov 17, 2022 11:25 am EDT. Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U. S. ReAlta To Participate at Oppenheimer Annual Healthcare Conference. Securities and Exchange Commission ("SEC"). Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Virtual Pediatric Endocrine Society 2020 Annual Meeting. Please see additional details below: Oppenheimer's Rare & Orphan Disease Summit. Oppenheimer rare and orphan disease summit 2009. Investor Contact: Corey Davis, Ph. Governance Highlights. Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.
Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, is conducting a Phase 2 trial in tuberous sclerosis complex, and has recently disclosed top line results from its Phase 2 proof-of-concept trial in PCDH19-related epilepsy. 2018 Annual Meeting of the Stockholders. Scientific Advisory Board. Investor Relations Contact: Daniel Ferry. Children With Relapsed or Refractory Malignant Cancer Clinical Study. H. Wainwright Virtual Investment Conference. Oppenheimer rare and orphan disease summit 2018. Norfolk, VA, February 22, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is scheduled to participate in the upcoming Oppenheimer 32nd Annual Healthcare Conference from March 15-17, 2022. LifeSci Communications, LLC.
March 27- April 1 20222022 Glycolipid and Sphingolipid Biology GRC. 2019 BIO Investor Forum Conference. UBS Global Healthcare Virtual Conference. Oppenheimer Healthcare is dedicated to finding and highlighting opportunities in Rare & Orphan Disease to investors. Waldenstrom's Macroglobulinemia Pivotal Study.
Explore Savara stock performanceReview stock information. February 7 – 1118TH ANNUAL WORLDSYMPOSIUM ON LYSOSOMAL DISEASE RESEARCH. Speakers: Scott Braunstein, M. D., Chief Executive Officer, and Steven Pfanstiel, Chief Financial Officer. Live webcasts of the presentations (where applicable) will be on the Investors page of the Company's website at. Historical Price Lookup. Piper Sandler Lung Day. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. François Ravenelle, PhD. Savara Fourth Quarter & Fiscal Year End 2017 Financial Results and Business Update Conference Call. CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.
Governance Documents. Time:||12:00 p. m. ET|. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. We will be at the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease CompaniesCompanies, New York, NY, September 23-24. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Something went try again later.
For more information, visit Forward‐Looking Statements. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Savara Inc. at at 28th Annual Oppenheimer & Co. Healthcare Conference. A replay of the webcast will be archived for 30 days following the presentation date. Canaccord Genuity Global Growth Conference. March 15 - 18, 2022Krabbe Translational Research Network Meeting. For more information, visit. Forward-Looking Statements.
Relapsed or Refractory Select B-Cell Malignancies Clinical Study. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. 2020 Biotech Showcase Conference. Date||Title and Summary||Additional Format|. Casma Therapeutics is harnessing autophagy by developing a novel degradation technology to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences: B. Riley Neuroscience Conference.